Advances in Combination Therapy for Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2026
Special Issue Editor
Interests: clinical lymphoma; cancer-vaccines; metronomic chemotherapy; exercise oncology
Special Issue Information
Dear Colleagues,
The therapeutic landscape of lymphoma is undergoing profound transformation thanks to the development of novel antibody-based treatments, including bispecific antibodies, agents targeting the CD47–SIRPα axis, anti-PD1-PDL1, and antibody–drug conjugates such as loncastuximab tesirine. When combined with chemotherapy, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, and other targeted drugs, these therapies have the potential to synergize distinct mechanisms of action, improve response rates, overcome resistance, and personalize patient care.
This Special Issue, “Advances in Combination Therapy for Lymphoma”, will highlight state-of-the-art preclinical and clinical advances in rational combinatorial approaches. Topics addressed will include innovative trial designs, predictive biomarkers, mechanistic studies, and real-world evidence supporting the integration of novel antibodies with established or emerging partners. Our goal is to provide a comprehensive resource for clinicians and researchers striving to optimize the efficacy and safety of lymphoma treatment.
We invite the submission of original research articles, reviews, and perspectives that explore the promise and challenges of combination therapy for lymphoma and contribute to shaping the next generation of treatment strategies.
Dr. Maria Christina Cox
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma
- combination therapies
- T-cell engagers
- immuno-conjugates
- targeted drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
